Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
546. |
ECCT/25/08/01 | MK-8527 as HIV-1 PrEP in Women A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women |
Principal Investigator(s) 1. Maricianah Onono Site(s) in Kenya 1. KEMRI-RCTP KISUMU (Kisumu county) 2. Kargeno Research and Policy Hub KEMRI-CMR KISUMU (Kisumu county) 3. KEMRI-PHRD, Thika (Kiambu county) 4. UW KNH - Rachuonyo County Hospital (Homa Bay county) |
View |
547. |
ECCT/25/08/02 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. KEMRI CMR RCTP (Kisumu county) |
View |
548. |
ECCT/25/08/03 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Uasin Gishu county) 3. KEMRI-WRP (Kericho county) 4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county) |
View |
549. |
ECCT/25/08/04 | MK-8527-010 PrEP A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once-Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) |
View |
550. |
ECCT/25/08/05 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Dr. Isaac Tsikhutsu Site(s) in Kenya 1. KEMRI WALTER REED KERICHO (Kericho county) 2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrudes Childrens Hospital (Nairobi City county) 5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 7. KEMRI Kondele Children\'s Hospital (Kisumu county) |
View |